Oct 1 2010
RepRegen™, the ‘smart biomaterials’ company, announced today that three- and six-month data from an in vivo study of its CE-marked StronBone™ Bone Graft Substitute with Strontium demonstrated by analytical testing that it can generate bone quality in, and around, bone defects that is significantly superior to a standard bone void filler (TCP-CaSO4) in the control defect.
Specifically, the study demonstrated:
- The bone in the defect was significantly stiffer (stronger) at 3 months (69%) in the StronBone bone graft than in the control (it took 6 months for the control to achieve a comparable stiffness); and,
- The bone in the defect was significantly denser at 3 months (41%) and 6 months (62%) in the StronBone bone graft than in the control.
The study further demonstrated:
- The amount of soft tissue in the defect at 3 months was significantly lower in the StronBone bone graft compared to the control (17% compared to 41%); and,
- The amount of soft tissue in the defect at 6 months was significantly lower in the StronBone bone graft compared to the control (12% compared to 40%).
This study demonstrates that StronBone™ Bone Graft Substitute results in rapid regeneration of high-quality bone and slower resorbtion of bone in vivo. It is this combined affect that makes StronBone™ Bone Graft Substitute perform so well.
The study was conducted by principal investigator Prof. Allen Goodship along with Prof. Gordon Blunn and colleagues. The data will be submitted for publication. The study and analysis was conducted at the Institute of Orthopaedics and Musculoskeletal Science at University College London (UCL), where Prof. Goodship is professor of Orthopaedic Sciences and Director of the Institute.
“Our platform is designed to dramatically upgrade the repair and regeneration of hard tissue such as bone,” said Ian Brown, RepRegen’s CEO. “We intend to begin commercializing the first product from our hard tissue platform this year.”
“The critical mass of positive data from in vitro and in vivo studies of RepRegen’s technology is compelling,” added RepRegen’s Chairman, Dr. Stephen Rietiker. “These latest results enhance RepRegen’s commercial push at the right time.”
Earlier this year, an in vitro study presented at the 56th Annual Meeting of the Orthopaedic Research Society (ORS) demonstrated that RepRegen’s patented Strontium-based bioactive glass platform enhances cellular attraction of osteoblasts to the matrix.